Evrysdi (Risdiplam)
What is a Generic Drug?
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Coming Soon – Save up to 85%
Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.
Prescription Required
-
Product Details
Description
Evrysdi (Risdiplam) is a medication used to treat spinal muscular atrophy (SMA). It works by helping produce a key protein called motor neuron 2 (SMN2), necessary for muscle growth and maintenance. Evrysdi is the first oral medicine approved for managing SMA. Healthcare providers may prescribe Evrysdi to adults, children, and infants to improve motor functions and increase survival rates for those with this genetic condition.
Directions
Evrysdi is taken orally on a daily basis after a meal, ideally at the same time each day for consistency. The dosage is adjusted based on the patient's weight, with special considerations for children under 2 years old or those weighing less than 20 kilograms or 44 pounds. The maximum daily dose of Evrysdi is 5 milligrams.
It is important to use the medication promptly as it must be discarded if not used within 5 minutes of drawing it into the oral syringe. Patients should not mix Evrysdi with formula or milk and should drink water after taking the medication to ensure complete ingestion. Contact with the skin or eyes should be avoided; if accidental contact occurs, the area should be thoroughly rinsed with water.
Ingredients
Risdiplam is the active ingredient in Evrysdi.
Contraindications
There are no listed contraindications on the Evrysdi medication label. However, those with a known hypersensitivity to Risdiplam or any ingredients of the formulation should avoid taking it.
Cautions
- Before beginning treatment with Evrysdi, it's important to discuss the following with your healthcare provider:
- Your current health conditions
- Any allergies you may have
- All medications you are currently using
- Whether you are pregnant or breastfeeding
- Avoid inhaling the dry powder or getting it on your skin or in your eyes. If contact occurs, wash your skin with soap and water and rinse your eyes with water.
- Always wear disposable gloves when preparing and cleaning up Evrysdi to prevent direct contact.
- Evrysdi can increase the levels of certain medications eliminated by MATE1 or MATE2-K transporters, such as metformin. Avoid using Evrysdi with these drugs when possible. If you must use them together, watch for signs of drug-related side effects and consider lowering the dose of the other drug.
- If you are pregnant or become pregnant while taking Evrysdi, you can participate in a pregnancy exposure registry to help monitor the effects of the medication on your pregnancy and the baby. You can register by calling 1-833-760-1098 or visiting the registry website.
Side Effects
Evrysdi may cause several side effects. The most frequent adverse reactions reported across different SMA patient groups include fever, diarrhea, and rash. Other common effects observed in clinical trials include upper respiratory tract infections, cough, constipation, and vomiting.
In addition to the common side effects, Evrysdi has potential serious adverse effects, particularly concerning mouth ulcers, joint pain (arthralgia), and urinary tract infections. While the medication has been studied extensively across various age groups and SMA types, its long-term safety profile continues to be monitored. Patients and caregivers should watch for worsening symptoms and report severe or persistent issues to healthcare providers promptly.
References:
- Evrysdi (Risdiplam) Product Monograph. South San Francisco, CA: Genentech, Inc.; 2024.
- Evrysdi (Risdiplam) Drug Label Information. South San Francisco, CA: Genentech, Inc.; 2024.
IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.Product Code : 14590
-
Product Reviews
